Tofacitinib is a new JAK inhibitor taken by mouth 10mg twice daily. Recent trials (OCTAVE) have shown significant benefit in patients with moderately active UC. The patients had previous failure or intolerance to conventional treatments. Patients receiving tofacitinib were significantly more likely to have a clinical response, healing of the colon or achieve remission than those given placebo tablets at weeks 2, 4 and 8. While this drug has been around some time, this is the latest and largest trial that has produced promising results. It is hoped that it will be licensed and made available for appropriate or selected patients towards the end of 2017.
At West Kent Gastroenterology, we work hard to provide our patients with top-class care. You will enjoy friendly, fast and modern treatment by a highly experienced gastroenterologist. We carefully review patient satisfaction and feedback, and at West Kent Gastroenterology we are continuously making improvements to our services, ensuring the highest level of care possible.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.